-
公开(公告)号：US20210047342A1
公开(公告)日：2021-02-18
申请号：US16916681
申请日：2020-06-30
Applicant: H. Lundbeck A/S
Inventor： John Paul Kilburn , Erhad Ascic , Mauro Marigo , Laurent David
IPC: C07D495/04
Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
-
公开(公告)号：US09682967B2
公开(公告)日：2017-06-20
申请号：US14763544
申请日：2014-01-27
Applicant: H. Lundbeck A/S
Inventor： Philip James Maltas , Stephen Watson , Morten Langg{hacek over (a)}rd , Laurent David
IPC: C07D409/04 , C07D213/75 , C07D215/38 , C07D333/66 , C07D401/04 , C07D403/04 , C07D237/20 , C07D239/42 , C07D241/20 , C07D277/46 , C07D213/40 , A61K31/44 , A61K31/4402 , A61K31/4406 , C07D417/04 , C07D213/60 , C07D213/65 , C07D333/68
CPC classification number: A61K31/44 , A61K31/381 , A61K31/426 , A61K31/4402 , A61K31/4406 , A61K31/47 , A61K31/4965 , A61K31/50 , A61K31/505 , C07D213/40 , C07D213/60 , C07D213/65 , C07D213/75 , C07D215/38 , C07D237/20 , C07D239/42 , C07D241/20 , C07D277/46 , C07D333/66 , C07D333/68 , C07D401/04 , C07D403/04 , C07D409/04 , C07D417/04
Abstract: The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motorneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.
-
公开(公告)号：US09393248B1
公开(公告)日：2016-07-19
申请号：US15071955
申请日：2016-03-16
Applicant: H. Lundbeck A/S , Vernalis (R&D) Ltd.
Inventor： Gitte Kobberøe Mikkelsen , Laurent David , Stephen Watson , Garrick Paul Smith , Douglas Stewart Williamson , I-Jen Chen
IPC: A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/497
CPC classification number: A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/497 , C07D401/04 , C07D401/14 , C07D403/14 , C07D413/04 , C07D413/14
Abstract: The present invention is directed to aminopyridine derived compounds of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such as a Lewy body dementia, Parkinson's disease or cancer.
Abstract translation: 本发明涉及衍生自式（A）的氨基吡啶衍生化合物。该化合物被认为可用于治疗与LRRK2相关的疾病，例如路易体痴呆，帕金森病或癌症。
-
公开(公告)号：US20220177557A1
公开(公告)日：2022-06-09
申请号：US17399205
申请日：2021-08-11
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjaergaard , Lars Østergaard Pedersen , Ayodeji Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Alfred Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , G01N33/68
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
公开(公告)号：US11111290B2
公开(公告)日：2021-09-07
申请号：US16585207
申请日：2019-09-27
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjaergaard , Lars Østergaard Pedersen , Ayodeji Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Alfred Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , G01N33/68 , A61K39/00
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
Patent Agency Ranking
公开(公告)号：US10472415B2
公开(公告)日：2019-11-12
申请号：US15645442
申请日：2017-07-10
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjærgaard , Lars Østergaard Pedersen , Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Alfred Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , A61K39/00 , G01N33/68
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
公开(公告)号：US20190284265A1
公开(公告)日：2019-09-19
申请号：US16371867
申请日：2019-04-01
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjaergaard , Lars Østergaard Pedersen , Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , G01N33/68
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
公开(公告)号：US11466027B2
公开(公告)日：2022-10-11
申请号：US16916769
申请日：2020-06-30
Applicant: H. Lundbeck A/S
Inventor： John Paul Kilburn , Erhad Ascic , Mauro Marigo , Laurent David
IPC: C07D495/04
Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
-
公开(公告)号：US20170239226A1
公开(公告)日：2017-08-24
申请号：US15584425
申请日：2017-05-02
Applicant: H. Lundbeck A/S
Inventor： Phillip James Maltas , Stephen Watson , Morten Langgård , Laurent David
IPC: A61K31/44 , A61K31/505 , A61K31/4965 , A61K31/50 , A61K31/4406 , A61K31/426 , A61K31/47 , A61K31/381 , A61K31/4402
CPC classification number: A61K31/44 , A61K31/381 , A61K31/426 , A61K31/4402 , A61K31/4406 , A61K31/47 , A61K31/4965 , A61K31/50 , A61K31/505 , C07D213/40 , C07D213/60 , C07D213/65 , C07D213/75 , C07D215/38 , C07D237/20 , C07D239/42 , C07D241/20 , C07D277/46 , C07D333/66 , C07D333/68 , C07D401/04 , C07D403/04 , C07D409/04 , C07D417/04
Abstract: The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motoneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.
-
公开(公告)号：US20160184317A1
公开(公告)日：2016-06-30
申请号：US15071955
申请日：2016-03-16
Applicant: H. Lundbeck A/S , Vernalis (R&D) Ltd.
Inventor： Gitte Kobberøe Mikkelsen , Laurent David , Stephen Watson , Garrick Paul Smith , Douglas Stewart Williamson , I-Jen Chen
IPC: A61K31/5377 , A61K31/4545 , A61K31/497 , A61K31/4439
CPC classification number: A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/497 , C07D401/04 , C07D401/14 , C07D403/14 , C07D413/04 , C07D413/14
Abstract: The present invention is directed to aminopyridine derived compounds of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.
Abstract translation: 本发明涉及衍生自式（A）的氨基吡啶衍生化合物。该化合物被认为可用于治疗与LRRK2相关的疾病如路易体痴呆，帕金森病或癌症。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.036 seconds)
